Link Medicine has a total of 47 patents globally, out of which 3 have been granted. Of these 47 patents, more than 6% patents are active. Israel is where Link Medicine has filed the maximum number of patents, followed by Europe (EPO). Parallelly, the USA seems to be the main focused R&D center of Link Medicine and is also the origin country of the firm.
Link Medicine was founded in the year 2005. The Company develops disease-modifying therapies for the treatment of neurodegenerative diseases.
Do read about some of the most popular patents of Link Medicine which have been covered by us in this article and also you can find Link Medicine patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Link Medicine patent portfolio.
How many patents does Link Medicine have?
Link Medicine has a total of 47 patents globally. These patents belong to 12 unique patent families. Out of 47 patents, 3 patents are active.
How Many Patents did Link Medicine File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
How many Link Medicine patents are Alive/Dead?
How Many Patents did Link Medicine File in Different Countries?
Where are Research Centres of Link Medicine Patents Located?
The R&D Centres of patents filed by Link Medicine is in the USA.
List of Link Medicine Patents
|Link Medicine Patents||Title|
|US7461363B2||System And Method For Analyzing Response Values Sum Of Differential Signals|
|EP2545919A1||Treatment Of Synucleinopathies|
|EP2155197A4||Treatment Of Lysosomal Storage Diseases|
|EP2358370A2||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|EP1968591A4||Treatment Of Synucleinopathies|
|WO2010141932A1||Aminopyrrolidinone Derivatives And Uses Thereof|
|WO2010057028A3||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|WO2010056985A3||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|WO2010057006A9||Azaquinolinone Derivatives And Uses Thereof|
|WO2009151683A3||Quinolinone Farnesyl Transferase Inhibitors For The Treatment Of Synucleinopathies And Other Indications|
|WO2009036275A1||Treatment Of Neurodegenerative Diseases Using Indatraline Analogs|
|WO2009018088A2||Imaging Of Alpha-Synuclein|
|WO2008112525A3||Treatment Of Lysosomal Storage Diseases|
|WO2008137692A1||Treatment Of Synucleinopathies|
|WO2007075923A3||Treatment Of Synucleinopathies|
|WO2007092285A2||Treatment Of Synucleinopathies|
|JP2012508765A||Treatment Of Proteinopathies With Farnesyltransferase Inhibitors|
|JP2009521470A5||Treatment Of Synucleinopathies|
|CA2743709A1||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|CA2634598A1||Treatment Of Synucleinopathies|
|AU2009313906A1||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|AU2006331542A1||Treatment Of Synucleinopathies|
|IL216768A||Aminopyrrolidinone Derivatives Compositions Comprising The Same And Uses Thereof|
|IL212835A||Compositions Comprising A Farnesyl Transferase Inhibitor For Use In Treating Proteinopathies|
|IL212836A||Azaquinolinone Derivatives, Compositions Comprising The Same And Uses Thereof|
|IL200792A||Compositions Comprising A Farnesyl Transferase Inhibitor And Use Thereof For Treating Lysosomal Storage Disease|
|IL192357A||Pharmaceutical Compositions Containing A Farnesyl Transferase Inhibitor|
|BRPI0920927A2||Azaquinolinone Derivatives And Uses Thereof|
|BRPI1010024A2||Aminopyrrolidinone Derivatives And Use Thereof|
|BRPI0921113A2||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|SG176628A1||Aminopyrrolidinone Derivatives And Uses Thereof|
|SG171236A1||Azaquinolinone Derivatives And Uses Thereof|
|SG171245A1||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|MX2011013016A||Aminopyrrolidinone Derivatives And Uses Thereof.|
|MX2011005096A||Azaquinolinone Derivatives And Uses Thereof.|
|MX2011005095A||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor.|
|MYPI2011005834A0||Aminopyrrolidinone Derivatives And Uses Thereof|
|MYPI2011002133A0||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|MYPI2011002130A0||Azaquinolinone Derivatives And Uses Thereof|
|HK1168348A||Aminopyrrolidinone Derivatives And Uses Thereof|
|HK1168093A||Azaquinolinone Derivatives And Uses Thereof|
|HK1123723A||Treatment Of Synucleinopathies|
|ZA201109034B||Aminopyrrolidinone Derivatives And Uses Thereof|
|ZA201103635B||Azaquinolinone Derivatives And Uses Thereof|
|ZA201103636A||Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor|
|IN10060DELNP2011A||Aminopyrrolidinone Derivatives And Uses Thereof|
|IN4486DELNP2011A||Azaquinolinone Derivatives And Uses Thereof|
What are Link Medicine key innovation segments?
What Technologies are Covered by Link Medicine?
The chart below distributes patents filed by Link Medicine in different countries on the basis of the technology protected in patents. It also represents the markets where Link Medicine thinks it’s important to protect particular technology inventions.
R&D Focus: How has Link Medicine search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!